Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

Rezolute Reports Fourth Quarter and Full Year

Fiscal 2021 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., September 15, 2021 (GLOBE NEWSWIRE) -

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative

therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth

quarter and fiscal full year ended June 30, 2021.

"We are very pleased with our overall progress, notably advancement

of our clinical programs including RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema," said Nevan Elam,

Chief Executive Officer and Founder of Rezolute. "We have continued to execute on the milestones we laid out prior to the COVID-19

pandemic, including the initiation of patient dosing in the second cohort of the Phase 2b trial of RZ358, and start of the Phase 1b multiple-ascending

dose study of RZ402. In addition to these clinical accomplishments, we have further strengthened our leadership team and Scientific Advisory

Board with key opinion leaders who will help us to advance our programs."

Recent Business Highlights

Fourth Quarter and Full Year Fiscal 2021 Financial Results

About Rezolute, Inc.

Rezolute is developing transformative therapies for metabolic diseases related to chronic glucose imbalance. The Company's lead

clinical asset, RZ358, is in Phase 2b development for treatment of congenital hyperinsulinism (HI), a rare pediatric endocrine disorder.

The Company is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain

forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act

and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe

harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this

statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe

future plans, strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe,"

"estimate," "expect," "intend," "plan," "project," "seek," "strive,"

"try," or future or conditional verbs such as "could," "may," "should," "will," "would,"

or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly,

actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking

statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no

obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements

Media and Investor Contact

Consolidated Financial Statements Data

thousands, except per share data)